Drug Profile
Pegfilgrastim biosimilar - Nanogen Biopharmaceutical
Alternative Names: PEGCYTELatest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 06 Nov 2017 Nanogen Biopharmaceutical completes a phase III trial in Neutropenia in Vietnam (NCT03381417)
- 06 Nov 2017 Nanogen Biopharmaceutical completes a phase I trial in Neutropenia in Vietnam (NCT03376503)
- 25 May 2016 Nanogen Biopharmaceutical initiates a phase I trial in Neutropenia in Vietnam (NCT03376503)